Scientists have developed a test that uses cells from a single donor’s blood to predict whether a new drug will cause a severe reaction in humans.
The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.
Cytokine storm reactions are a particular worry for new biological therapies, or “biologics”, which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don’t materialise in animal studies, so tests on human cells are essential.
However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.
Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.
Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor’s own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.
The new method is better as it only requires blood from one donor and doesn’t mix cells from different people, with the advantage of making a more reliable test.
Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: “As biological therapies become more mainstream, it’s more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We’ve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.
“Drug companies have the technical capacity to start using this test now, but we’re working on developing an off-the-shelf kit which will make it easy to use on a large scale.”
Dr Daniel Reed, the first author on the study, said: ”A further benefit of this new technology is that personalised therapies can be tested to see how safe and effective they will be for an individual.”
The Latest on: Personalised therapies
via Google News
The Latest on: Personalised therapies
- WizeCare Partners with Essen Health Care to Advance Value-Based Care Through Personalized All-In-One Telerehabilitation Platformon October 15, 2021 at 7:30 am
WizeCare, a health technology company that establishes a new paradigm of physical rehabilitation, is helping patients achieve optimal results in their recovery for orthopedic, neurological, and ...
- The Compression Therapy Devices Market To Steal The Growth Show (US$ 3,232.3 Million) Through Innovation Between 2021on October 14, 2021 at 1:06 pm
The Compression Therapy Devices Market is bound to reach US 2 929 8 Million at a CAGR of 5 6 between 2025 The modern day situation says that the healthcare sector is witnessing an optimization and ...
- Exscientia AI study spots which blood cancer therapies work and which don’ton October 14, 2021 at 8:27 am
Using AI in personalized medicine could boost treatment success in patients with aggressive blood cancers, an Exscientia study found. The method follows a basic idea: Take a test to see whether a drug ...
- RIESTER RX, a New Pharma Comms Division Aims to Help Improve Lives with Personalized Campaignson October 14, 2021 at 6:52 am
Strengthening the connection between patients and pharmaceutical brands through campaigns with an increased focus on empathy, understanding and purpose has the potential to make a life-changing and ...
- The Proton Therapy Systems Market To Witness Calculated Innovationon October 13, 2021 at 7:52 pm
The global Proton Therapy Systems Market is there to grow at a noteworthy In Upcoming Years These days pre empt process breakdowns by making use of AI are the ongoing trend Regulatory compliance is ...
- At initial cancer diagnosis, a deeply personalized assessmenton October 13, 2021 at 3:12 pm
UC San Diego researchers report that conducting genomic evaluations of advanced malignancies can be effective in guiding first-line-of-treatment, rather than waiting until standard-of-care therapies ...
- At initial cancer diagnosis, a deeply personalized assessment can help guide treatment planon October 13, 2021 at 1:40 pm
In treating cancer, personalized medicine means recognizing that the same disease can behave differently from one patient to another, and precision medicine means that diagnosis and treatment should ...
- Ampersand and Calpro partner to push personalized IBD therapy across the NHSon October 10, 2021 at 5:00 pm
Calpro AS and Ampersand Health Ltd. are combining technologies to provide a self-management and remote monitoring solution for people with inflammatory bowel disease (IBD). The partnership will ...
- Personalized Therapy Biosimulation Market Size to Reach USD 3,164.1 Million in 2028 | Emergen Researchon October 5, 2021 at 3:12 am
The global personalized therapy biosimulation market size reached USD 1,061.7 Million in 2020 and is expected to register a significant revenue CAGR during the forecast period, according to latest ...
- Towards Personalized Cell-Replacement Therapies for Brain Repairon September 28, 2021 at 5:00 pm
constitute a major advancement towards personalized cell-replacement therapies via autologous transplantation, and is expected to lead to clinically applicable solutions in the future. Schwann ...
via Bing News